Denmark - Re-Imbursed Pharmaceutical Market
Since 2014, Denmark Re-Imbursed Pharmaceutical Market grew 6.9points year on year. In 2019, the country was ranked number 11 comparing other countries in Re-Imbursed Pharmaceutical Market at 21.5 Percent of Generics in Value. Denmark is overtaken by Spain, which was ranked number 10 at 23.6 Percent of Generics in Value and is followed by Switzerland with 20.4 Percent of Generics in Value. Austria topped the ranking with 52.2 Percent of Generics in Value in 2019, that is an increase of 2.8points versus 2018. United Kingdom, Turkey and New Zealand respectively ranked number 2, 3 and 4 in this ranking. Denmark witnessed the best average annual growth at +6.9points per year, while Slovakia was the worst growing country at -7.8points per year.
Loading...
| Date | Percent of Generics in Value |
|---|---|
| 2019 | 21.50 |
| 2018 | 18.80 |
| 2017 | 17.40 |
| 2016 | 17.70 |
| 2015 | 18.10 |
How does Denmark rank in Re-Imbursed Pharmaceutical Market?
| # | 17 Countries | Percent of Generics in Value | Last | YoY | 5‑years CAGR | ||
|---|---|---|---|---|---|---|---|
| 1 |
#1
Austria
|
52.20 % | 2019 | +2.8 % | +2.2 % | View data | |
| 2 |
#2
United Kingdom
|
38.50 % | 2019 | +2.1 % | +2.6 % | View data | |
| 10 |
#10
Spain
|
23.60 % | 2019 | +5.4 % | +1.6 % | View data | |
| 11 |
#11
Denmark
|
21.50 % | 2019 | +14.4 % | +6.9 % | View data | |
| 12 |
#12
Switzerland
|
20.40 % | 2019 | +1.5 % | +1.5 % | View data | |